HELIOS Klinikum Berlin-Buch GmbH
- Address
- lock Available on a paid plan
Female Urogenital Diseases and Pregnancy Complications
The obstetrics and gynecology department conducts trials focused on breast cancer. It also investigates endometrial cancer and explores new options for ovarian cancer.
- Advanced breast cancer
- Hormone receptor‑positive early breast cancer
- High‑risk endometrial cancer
- Platinum‑resistant ovarian cancer
These studies seek to enhance survival outcomes and personalize therapy for women facing malignancies of the reproductive system.
Neoplasms
Research at the site spans a broad range of solid tumours. It includes studies on renal cell carcinoma. Investigators also evaluate colorectal cancer and explore new options for soft‑tissue sarcoma.
- Clear cell renal cell carcinoma
- BRAF‑mutant colorectal cancer
- Advanced soft‑tissue sarcoma
- Metastatic triple‑negative breast cancer
The emphasis is on improving progression‑free survival and assessing safety of emerging therapies across diverse cancer types.
Hemic and Lymphatic Diseases
The hematology unit is engaged in studies targeting acute lymphoblastic leukemia. It also focuses on diffuse large B‑cell lymphoma and evaluates novel approaches for multiple myeloma.
- Philadelphia‑positive ALL
- Relapsed diffuse large B‑cell lymphoma
- Newly diagnosed multiple myeloma
- High‑grade B‑cell lymphoma
These trials aim to increase remission rates and reduce treatment‑related complications for patients with blood‑cancer disorders.
Immune System Diseases
Investigations include autoimmune conditions such as juvenile idiopathic arthritis and uveitis, evaluating biologic agents to control inflammation and preserve joint function.
- Systemic juvenile idiopathic arthritis
- Juvenile psoriatic arthritis
- Baricitinib in JIA‑associated uveitis
- Bimekizumab pharmacokinetics in pediatric arthritis
The objective is to establish safer, more effective therapies that improve quality of life for patients with immune‑mediated diseases.
Musculoskeletal Diseases
The department studies rare musculoskeletal tumors such as tenosynovial giant cell tumor and high‑risk sarcomas, testing new inhibitors to halt disease progression.
- Tenosynovial giant cell tumor
- Unresectable soft‑tissue sarcoma
- Rhabdoid tumor
- Desmoid tumor
Research seeks to expand therapeutic options where conventional surgery or chemotherapy offers limited benefit.
Digestive System Diseases
Gastro‑enterology trials evaluate gastric adenocarcinoma and colorectal cancer with innovative immunotherapy combinations.
- Gastric cancer
- Colorectal cancer with BRAF V600E mutation
- Gastroesophageal junction adenocarcinoma
- Advanced colorectal carcinoma
The focus is on enhancing response rates and identifying biomarkers that predict benefit from novel treatments.
Skin and Connective Tissue Diseases
Trials include patients with chronic venous ulcers, assessing topical regenerative products to accelerate wound closure.
- Chronic venous ulcers
- Cutaneous manifestations of autoimmune disease
- Skin toxicity management in cancer therapy
- Connective tissue disorder monitoring
These studies aim to improve healing outcomes and reduce complications associated with skin integrity.
Environment and Public Health
The site participates in public‑health research examining environmental risk factors for cancer incidence and strategies for community health promotion.
- Environmental exposure assessment
- Population screening programs
- Health education initiatives
- Epidemiologic surveillance of malignancies
Findings support evidence‑based policies to reduce disease burden and enhance preventive care in the Berlin region.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 217 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 211 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 44 by active trials.
- 1GPOH gGmbH6active
lock +43 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC7trials
lock +29 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HELIOS Klinikum Berlin-Buch GmbH
lock Showing 1 of 123 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 217 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 20 | Unknown | 2015-06-02 | 2025-12-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.